Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

68 evidence topics · 30 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.